antimicrobial resistance and healthcare-associated infections european antimicrobial resistance surveillance Network (ears-Net):
The EARS-Net is a network of national surveillance systems providing reference data on antimicrobial resistance in invasive bacterial pathogens from clinical laboratories in the EU/EEA Healthcare-associated infections surveillance Network-supporting capacity building for the surveillance of clostridium difficile infections (Hai-Net cDi): Outsourced microbiological support to hospital-based surveillance of CDI aims to increase the capacity of laboratories in EU/EEA Member States to (1) perform CDI diagnostic practices with high diagnostic accuracy and (2) acquire comparable typing data from C. difficile isolates emerging and vector-borne diseases emerging viral Diseases-expert Laboratory Network (evD-LabNet): The EVD-LabNet is strengthening capacity for early detection and surveillance of (re) emerging viral diseases in the EU/EEA countries and EU Candidate Countries. It provides scientific advice to ECDC and works in close collaboration with other Commission initiatives. Formerly named "European Network for Diagnostics of Imported Viral Diseases" (ENIVD)
Food-and waterborne diseases, zoonoses european Food-and Waterborne Diseases and Zoonoses Network (FWD-Net): The FWD-Net network advises ECDC and contributes to strengthening surveillance and prevention of 21 food-and waterborne diseases and zoonoses in the EU/EEA, in close collaboration with EFSA, WHO and global public health partners. Activities include microbiology capacity building, EQA schemes, and harmonization of laboratory-based surveillance including molecular/genomic typing european Legionnaires' Disease surveillance Network (eLDsNet): The ELDSNet carries out surveillance of Legionnaires' disease in the EU/EEA and supports microbiology capacity building, including diagnostics and molecular typing, in close collaboration with WHO and global public health partners creutzfeldt-Jakob Disease international surveillance Network (eurocJD): The EuroCJD is coordinated from the National CJD Surveillance Unit in Edinburgh with funding by the ECDC. It provides advanced diagnostic services for those Member States that lack diagnostic capability for transmissible encephalopathies and carries out surveillance of variant Creutzfeldt-Jakob disease (vCJD) in the EU/EEA Hiv, sexually transmitted infections and viral hepatitis european Gonococcal antimicrobial surveillance Programme (euro-GasP): The Euro-GASP network carries out sentinel surveillance of gonococcal antimicrobial resistance in the EU/EEA and is strengthening capacity for gonococcal culture and antimicrobial susceptibility testing through laboratory training and EQA schemes. In addition the network performs molecular typing of Neisseria gonorrhoeae influenza european reference Laboratory Network for Human influenza (erLi-Net): The ERLI-Net sub-network of reference laboratories of the European Influenza Surveillance Network carries out virological surveillance of human influenza in the EU/EEA and strengthening laboratory capacity for influenza virus detection, antiviral susceptibility testing, and typing, in close collaboration with WHO tuberculosis european reference Laboratory Network for tuberculosis (erLtB-Net):
The ERLTB-Net sub-network of reference laboratories from EU/EEA Member States supports harmonization of methods and laboratory capacity for tuberculosis diagnosis, antimicrobial susceptibility testing and molecular/ genomic typing (Continued) To strengthen the quality of surveillance and threat detec tion, ECDC has commissioned in the last 7 years 121 EQA exer cises for it's laboratory network members ( Table 2) . These EQAs covered a range of methods from pathogen detection and/or identification, molecular typing, to antimicrobial susceptibility testing (AST). EQAs was rated as one of the highest valued ECDC capacity building activities by external stakeholders (8), with its certificates being used for laboratory accreditation at the national level. EQA results over the years indicate better performance across countries, even though gaps remain (9) (10) (11) (12) . Having the networks centralized at ECDC has facilitated harmonization of EQA practice and cost efficiency across networks.
raPiD DetectiON OF eMerGiNG iNFectiOUs tHreats, 2012-2017
At the request of the European Commission or the Member States, EU laboratory networks together with ECDC participate in investigations and risk assessment of potential crossborder health threats caused by emerging diseases or outbreaks. Recent events illustrate how laboratory detection capacity developed across networks contributed to a coordinated public health management of threats in Europe and beyond.
In September 2012, a novel coronavirus was isolated from two cases of acute severe respiratory illness who had traveled to or resided in Saudi Arabia (13, 14) . Within a few weeks, more cases were identified in patients with links to the Middle East. This virus was named Middle East respiratory syndrome corona virus (MERSCoV) (15) . In November 2012, realtime reverse transcriptase (RT)polymerase chain reaction (PCR) detection and identification tests were developed to ensure rapid detection capability (14) . Technical protocols and positive RNA control material were made available by the European Commission funded European Virus Archive project and distributed within the former ECDC funded "European Network for Diagnostics of Imported Viral Diseases" (ENIVD). ECDC, in collaboration with WHO Regional Office for Europe (WHO/Europe), surveyed detection capability for MERSCoV by virology reference labora tories (16). Ten months after the virus discovery, laboratories had diagnostic capabilities in 24 of the 30 EU and European Economic Area (EEA) countries (17) . In 2013, an ECDC EQA exercise showed correct performance in laboratories across the ENIVD (18) . In 2015, 28 EU/EEA countries had capability to screen and confirm MERSCoV cases for appropriate management (7) . By October 2015, 14 cases of MERS had been diagnosed across seven EU countries among patients with connection with the MiddleEast. Thanks to rapid diagnosis, patients were promptly isolated and secondary transmission to household members or hospital patients occurred only rarely (19) .
In March 2013, fatal cases of human infection with novel reassortant avian influenza virus strain A(H7N9) following contact with infected poultry were reported in China (20) . This was the first time that human infection and deaths due to a low pathogenicity avian influenza virus had been identified. Within 1 month of this event, ECDC, the European Reference Laboratory Network for Human Influenza (ERLINet) coordinated by ECDC, and the WHO/Europe released a joint technical note on diagnostic preparedness for detection of these viruses (21) . In May 2013, the capability of ERLINet laboratories to detect and subtype the novel avian influenza A(H7N9) viruses was jointly assessed by ERLINet, ECDC, and WHO/Europe (22) . The sur vey showed that the generic influenza A virus detection and H7 and N9 subtyping assays used in 24 laboratories in 19 EU/EEA countries were adequate. Later in 2013, the results of an ECDC EQA confirmed that 33 of the 36 ERLINet laboratories correctly detected, typed, and subtyped the novel A(H7N9) influenza viruses (23) . In 2015, EULabCap survey results documented that diagnostic capability for avian influenza A(H7N9) virus infection existed in 28 of 29 EU/EEA countries, suggesting that the ERLI Net response support had facilitated Europeanwide laboratory compliance with ECDC/WHO influenza surveillance guidance (7) . No human influenza case caused by this strain has yet been diagnosed in Europe but annual epidemics of human infections in China indicate a persisting risk.
In December 2013, the largest ever epidemic of Ebola virus disease (EVD), started in Guinea and quickly spread to neigh boring West African countries where it caused over 10,000 deaths until controlled March 2016. In March 2014, as part of global assistance efforts, the EU allocated funding and deployed medical and laboratory staff and supplies in West Africa. The European Mobile field Laboratory (EMLab), an initiative by the International Cooperation and Development Office of the European Commission, established field diagnostic facilities in the affected countries to support patient screening (24) . Between March 2014 and October 2015, more than 19,000 samples were tested in these laboratories (24) . Deployment of an EMLab unit close to an Ebola Treatment Unit decreased the average turna round time from reception of a sample to diagnostic result to 4 h instead of several days. Several EUfunded laboratory networks worked to ensure capacity for testing suspected cases of EVD both in Africa and in travelers returning from the epidemic affected areas. These included the ENIVD network and the Joint Action "Quality Assurance Exercises and Networking on the Detection of Highly Infectious Pathogens" (QUANDHIP) which (26) . During the epidemic, five cases of EVD were confirmed in repatriated patients from West Africa and three new cases were diagnosed in the EU, including two travelassociated cases and one noso comial case in a healthcare provider (27) . These data confirmed that EVD patient isolation measures based on rapid diagnostics interrupt virus transmission and mitigate the risk of spread from patients evacuated to EU countries. In 2015, a novel healthcareassociated disease was discovered in Switzerland by Sax et al., who reported a hospital outbreak of cardiovascular infection caused by Mycobacterium chimaera in surgery patients, linked to contaminated heatercooler units used in surgery (28) . This environmental mycobacterium is difficult to detect (i.e., fastidious) and identify (i.e., need for DNA sequence analysis). In April 2015, following the report of similar cases of infection in the Netherlands, Germany and the UK, ECDC evaluated the risk across Europe (29) . It advised performing diagnostic investigations to ascertain possible cases of post surgical infections by this organism (29) . In collaboration with experts from the affected countries, ECDC followedup national investigations and published an EU casedefinition and technical protocol for case detection, laboratory diagnosis, environmental testing, and molecular typing of M. chimaera infection (30) . This protocol provided a basis for harmonized data collection across Europe to facilitate the sharing of information on the extent and the molecular epidemiology of the outbreak. In 2015 and 2016, M. chimaera strains were included in the EQA panel of the ECDC coordinated European Reference Laboratory Network for Tuberculosis (ERLTBNet). An updated risk assessment by ECDC indicated that, by November 2016, 52 cases of invasive cardiovascular infection by M. chimaera had been documented across seven European countries (31) . Investigations using wholegenome sequencing (WGS) of clinical and environmental isolates were conducted in several countries by national public health agencies in collaboration with device manufacturers. Their concordant findings consistently pointed to airborne dispersal of M. chimaera from a particular model of heater-cooler device as the most likely infection source in most cases. The device was found to be contaminated at the manufacturing plant with M. chimaera of the same genotype as in outbreakrelated patients (32) (33) (34) . Following replacement or repositioning of the device in the operating theater, no further case has been detected in the affected surgical care facilities so far.
aDvaNciNG LaBOratOrY-BaseD sUrveiLLaNce FOr cOMMUNicaBLe Diseases aND aNtiMicrOBiaL resistaNce
To overcome inconsistency in categorizing antimicrobial resis tance across countries, the European Committee for Anti micro bial Susceptibility Testing (EUCAST) operating under the joint auspices of ECDC and the European Society of Clinical Microbiology and Infectious Diseases has developed standard methods and nomenclature and advocated their use for in vitro AST of bacteria and fungi of medical interest. They have published evidencebased criteria for categorization of clinical isolates as wildtype/nonwild phenotype or clinically susceptible/resistant to antimicrobial agents (35) . In 2012, EU case definitions enforced the EUCAST clinical breakpoints for surveillance of antimicrobial resistance in humans (6) . Between 2011 and 2015, use of EUCAST breakpoints has rapidly progressed in clinical microbiology labo ratories across Europe (36) . The percentage of EU clinical laborato ries reporting to the ECDC coordinated European Antimicrobial Resistance Surveillance Network (EARSNet) which are using EUCAST susceptibility breakpoints increased from 29 to 84% over this 5year period (37, 38) . Likewise, the percentage of national reference laboratories participating in the ECDC coordinated European Gonococcal Antimicrobial Surveillance Programme (EuroGASP) that use EUCAST breakpoints increased from 62 to 85% from 2014 to 2016 (12, 39) . This harmonization across laboratories, encouraged by ECDC, improves the quality of sur veillance of antimicrobial resistance in Europe.
Because antimicrobial resistance in zoonotic pathogens is transferable from food animals to humans, OneHealth monitor ing, covering microbiota from human, animal, and environmen tal sectors in a holistic approach, is essential for containment. Unfor tunately, comparisons between antimicrobial resistance data from humans, food, and animals have long been hampered by the use of different test methods and interpretative criteria in each health sector. Whereas AST results on human isolates is interpreted with clinical breakpoints, those from healthy animal and food isolates monitoring are interpreted based on epidemio logical cutoff values (ECOFFs). These cutoff values distinguish normally susceptible isolates (wildtype phenotype) from those who have acquired resistance to the antimicrobial (nonwild type phenotype). In 2013, ECDC together with national repre sentatives from its Food and Waterborne Diseases and Zoonoses (FWD) network developed an EU protocol for harmonized monitoring of antimicrobial resistance in Salmonella enterica and Campylobacter jejuni and C. coli from human isolates, aiming at increasing the quality and comparability of data collected in the EU Member States by ECDC with those collected by the European Food Safety Authority (EFSA) from the veterinary sector. This protocol defines the panel of antimicrobials, the test methods, and reporting of quantitative susceptibility data to allow direct comparison with animal isolates' data interpreted with ECOFF values (40) . Between 2013 and 2015, the proportion of reporting countries compliant with the EU protocol doubled from 30 to 60%, improving comparability of antimicrobial resistance surveil lance data among sectors (41) .
Limiting the dissemination of multidrugresistant bacterial pathogens requires a better understanding of the emergence and mode of spread of resistance determinants. To this end, ECDC is undertaking panEuropean molecular epidemiology surveys. In 2012, addressing the most threatening carbapenem resist ance problem, the ECDC commissioned the European Survey of Carbapenemaseproducing Enterobacteriaceae (EuSCAPE) among a consortium of hospitals to assess the prevalence and geographical distribution of carbapenemaseproducing Ente robacteriaceae (CPE) characterized at the genetic level across 38 countries (42, 43) . The project demonstrated the feasibility of con ducting integrated epidemiological and microbiological sentinel multicenter surveys and of collecting qualityassured data for EU level analyses (43) (44) (45) . It also built national capacities across Europe for standardized laboratory detection, identification, and surveillance of CPE (42) . In 2015, all EU/EEA countries had nominated a national reference laboratory and operated national surveillance for CPE (44) . The EuSCAPE surveys revealed a rapid dissemination of carbapenemaseproducing Klebsiella pneumo niae around Europe, with wide variations by country in the type of carbapenemase, and the number of countries reaching an interregional or endemic level doubling from 6 to 13 countries over the period 2013-2015 (44, 45) .
Rising multidrug resistance also imperils the control of gonococcal infections worldwide. Since 2009, EuroGASP moni tors emerging resistance in Neisseria gonorrhoeae to therapeutic antimicrobials. The program is using a standardized methodo logy across the EU/EEA which integrates epidemiological and microbiological data to understand the risk factors associated with resistance and thereby inform intervention strategies (39) . For AST, the EuroGASP uses a hybrid approach of EU central ized and decentralized national testing (39) . EQA and training activities helped standardize surveillance across Europe: between 2009 and 2014, the number of EU/EEA countries participating in EuroGASP increased from 17 to 23 countries while the number of countries providing qualityassured (decentralized) testing increased from 3 to 17. In addition, EuroGASP also piloted molecular typing to unravel associations between clonal type and antimicrobial resistance profiles that could aid understanding of the dissemination of resistance within at risk populations (46) . EuroGASP results have revealed rapidly changing patterns of N. gonorrhoeae resistance to drugs of choice across Europe, leading to the revision of European and national gonorrhea treat ment guidelines and development by ECDC of the "Response plan to control and manage the threat of multidrugresistant gonorrhoea in Europe" (47) .
iNteGratiON OF MOLecULar aND GeNOMic tYPiNG iN eUrOPeaN sUrveiLLaNce aND ePiDeMic iNvestiGatiONs
Wholegenome sequencing is empowering highprecision infec tious disease surveillance and control (48) . ECDC developed multiannual roadmaps for the integration of molecular typing data on highpriority pathogens into its EU surveillance and epidemic preparedness systems, factchecking the feasibility, and capacity in the EU countries, in synergy with thirdparty activities along a global OneHealth partnership (49) (50) (51) . The addedvalue of molecular surveillance and WGSbased outbreak investigation was demonstrated following the introduction among the ECDC FWD public health laboratory surveillance network of a novel MultiLocus Variable Number Tandem Repeat Analysis (MLVA) typing scheme for Salmonella Enteritidis (52) . Increases in salmo nellosis cases with an uncommon MLVA profile were posted first by Scotland and then by the Netherlands in January and August 2016 in the Epidemic Intelligence Information System (53, 54) . Several other countries reported detection of this MLVA profile. WGS analysis performed either by national reference laboratories or in a central facility through ECDC support confirmed a multi country outbreak involving two distinct Salmonella Enteritidis genomic types. An outbreak investigation team involving affected countries, ECDC, and EFSA agreed on the outbreak case defini tion based on WGS and MLVA types, assessed the magnitude of the outbreak, and identified response options. At least 18 EU/EEA countries were affected by the outbreak. Environmental and food investigations by the food safety authorities showed that food establishments or retail shops in eight EU countries had received eggs contaminated with Salmonella Enteritidis of the epidemic MLVA or WGS types from farms located in one EU country (53) .
OUtLOOK
Whether for health protection or for food safety, we rely on microbiology laboratories to detect, identify, and characterize human pathogens of public health significance. Although health services are a national responsibility in the EU, a cost-benefit analysis study by the European Commission has concluded that the benefits of maintaining EU public health reference laboratory networks were likely to outweigh the costs, both from a Member State and from an EU perspective (55) . As outlined in the examples above, EU laboratory networks coordinated by ECDC as well as the European Commission over the last years have brought public health added value through fitforpurpose harmonization and validation of laboratory methods, quality assurance and training activities as well as contribution to preparedness and response for biological threats. The EULabCap surveys concluded that the EU/ EEA as a whole has a strong and improving public health micro biology system (7). Its key assets include harmonized methods for AST, extensive reference laboratory services, and laboratory inputs within national and EU surveillance networks. The use of molecular typing for surveillance and laboratory participation in outbreak response showed significant progress. In an era of rapid progress in electronic recording and transmission of health data, it is noticeable that half of the EU/EEA countries have implemented automated electronic reporting of microbiology laboratory data to their national communicable disease or antimicrobial resistance surveillance systems (7) . To track the transmission of resistance genes needed for targeted control measures, ECDC has developed a protocol for genomicbased surveillance of carbapenemresistant and/or colistinresistant Enterobacteriaceae at the EU level (56) . To deliver their full potential, these encouraging developments require sustained innovation in molecular diagnostic and typing methods and the collaborative engineering of wider connectivity between laboratory and public health information systems from the local to the global level. Collaboration between clinical and public health practitioners, government agencies, and academic institutions is key to develop integrated clinical, epidemiological, and molecular microbiological data collection, recording and exchange protocols as well as build the integrated information technology infrastructure enabling real time, molecular epide miologic surveillance, and alert systems for infectious diseases. ECDC as convener, funding source and coordinator in close part nership with multidisciplinary experts from EU disease networks continues to act as catalyst for translating these novel approaches into practice and further strengthening the collective laboratory capability for disease control in the EU.
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